Sirio Pharma Co., Ltd. (SHE:300791)
China · Delayed Price · Currency is CNY 21.67
-0.28 (-1.28%)
At close: Feb 13, 2026
Sirio Pharma Cash Flow Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
Period Ending | Sep '25 Sep 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 |
Net Income | 345.53 | 325.06 | 281.04 | 212.29 | 231.83 | 257.37 |
Depreciation & Amortization | 217.76 | 217.76 | 256.96 | 131.74 | 104.06 | 79.72 |
Other Amortization | 70.68 | 70.68 | 6.08 | 4.64 | 2.54 | 1.56 |
Loss (Gain) From Sale of Assets | -0.24 | -0.24 | -0.03 | 5.34 | -0.16 | 0.01 |
Asset Writedown & Restructuring Costs | 4.41 | 4.41 | 0.95 | 0.17 | -0.56 | 1.39 |
Loss (Gain) From Sale of Investments | 28.96 | 28.96 | 52.06 | -21.76 | -24.14 | -19.66 |
Stock-Based Compensation | 5.28 | 5.28 | 1.73 | -3.99 | - | - |
Provision & Write-off of Bad Debts | 0.32 | 0.32 | 5.06 | 3.99 | 0.96 | 3.54 |
Other Operating Activities | 138.02 | 29.92 | -8.24 | 20.6 | 34.19 | 7.02 |
Change in Accounts Receivable | -57.38 | -57.38 | -125.21 | -75.05 | -75.34 | -93.81 |
Change in Inventory | -5.72 | -5.72 | -59.3 | 3.56 | 22.89 | -65.04 |
Change in Accounts Payable | 17.28 | 17.28 | 6.57 | 82.14 | 8.93 | 117.17 |
Change in Other Net Operating Assets | -7.54 | -7.54 | -18.24 | 68.33 | 21.37 | 12.26 |
Operating Cash Flow | 695.53 | 566.97 | 386.08 | 444.86 | 341.38 | 319.57 |
Operating Cash Flow Growth | 84.96% | 46.85% | -13.21% | 30.31% | 6.82% | 37.98% |
Capital Expenditures | -489.27 | -412.13 | -451.7 | -293.69 | -524.68 | -223.14 |
Sale of Property, Plant & Equipment | 5.56 | 4.92 | 2.74 | - | 0.45 | 0.02 |
Cash Acquisitions | - | - | -707.54 | -21.63 | - | - |
Investment in Securities | 4.2 | 101 | -103.17 | 680 | -238 | -190 |
Other Investing Activities | -18.43 | -21.77 | 101.82 | -80.77 | 26.75 | 18.15 |
Investing Cash Flow | -497.94 | -327.98 | -1,158 | 283.91 | -735.48 | -394.98 |
Short-Term Debt Issued | - | - | - | - | 1,016 | 18.55 |
Long-Term Debt Issued | - | 271.47 | 97.22 | 0.03 | - | - |
Total Debt Issued | 261.14 | 271.47 | 97.22 | 0.03 | 1,016 | 18.55 |
Short-Term Debt Repaid | - | - | - | - | -31.95 | -83.38 |
Long-Term Debt Repaid | - | -186.11 | -17.42 | -9.42 | -6.16 | -0.21 |
Total Debt Repaid | -301.52 | -186.11 | -17.42 | -9.42 | -38.11 | -83.59 |
Net Debt Issued (Repaid) | -40.38 | 85.36 | 79.8 | -9.38 | 978.06 | -65.04 |
Issuance of Common Stock | 19.28 | 3.1 | 13.54 | 6.6 | 3.35 | - |
Repurchase of Common Stock | -8.92 | -8.92 | -31 | - | - | - |
Common Dividends Paid | -172.38 | -219.63 | -83.83 | -76.09 | -72.53 | -25.86 |
Other Financing Activities | -16.66 | 9.24 | -69.66 | 0.97 | -2.76 | -2.01 |
Financing Cash Flow | -219.06 | -130.84 | -91.15 | -77.9 | 906.11 | -92.91 |
Foreign Exchange Rate Adjustments | 6.42 | 2.5 | -4.59 | 29.86 | -11.27 | -12.16 |
Net Cash Flow | -15.05 | 110.64 | -867.52 | 680.72 | 500.74 | -180.48 |
Free Cash Flow | 206.27 | 154.84 | -65.62 | 151.17 | -183.31 | 96.43 |
Free Cash Flow Growth | - | - | - | - | - | 49.03% |
Free Cash Flow Margin | 4.63% | 3.68% | -1.83% | 6.03% | -7.74% | 4.67% |
Free Cash Flow Per Share | 0.68 | 0.51 | -0.21 | 0.49 | -0.57 | 0.32 |
Cash Income Tax Paid | 95.84 | 67.11 | 88.45 | 9.16 | 85.05 | 28.79 |
Levered Free Cash Flow | 128.96 | 36.64 | -211.19 | 24.38 | -289.58 | 442.13 |
Unlevered Free Cash Flow | 189.77 | 96.03 | -162.14 | 51.11 | -280.87 | 443.25 |
Change in Working Capital | -115.17 | -115.17 | -209.52 | 91.83 | -7.36 | -11.37 |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.